Xoma: A New Chance for Resurrection?
October 2, 2015
0
– Exclusively licenses global rights to its (TGFb) antibody program to Novartis – Could the lucrative agreement spare Xoma the pain of raising money for developing its programs, or filing bankruptcy? – Reasons to believe that Xoma’s TGFb therapeutic antibodies might become another cancer immunotherapy used alone or in combination with immune checkpoint protein inhibitors such as PD-1 inhibitors, which are considered game changers in …